LeMaitre Vascular, Inc. $LMAT Stock Bought by ProShare Advisors LLC

Key Points

• ProShare Advisors increased its LeMaitre Vascular stake by 36.2% in the third quarter, ending the period with 102,571 shares worth about $8.47 million. Institutional investors collectively own 84.64% of the company.
• LeMaitre reported quarterly EPS of $0.65, below the $0.69 analyst consensus, while revenue of $67.97 million beat estimates and rose 11.3% year over year.
• Analysts have a consensus “Hold” rating and an average price target of $110.60. The company also announced a quarterly dividend of $0.25 per share, equivalent to a 1.1% yield.

ProShare Advisors LLC lifted its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 36.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 102,571 shares of the medical instruments supplier's stock after acquiring an additional 27,270 shares during the period. ProShare Advisors LLC owned approximately 0.45% of LeMaitre Vascular worth $8,471,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of LMAT. BlackRock Inc. acquired a new position in LeMaitre Vascular during the 2nd quarter valued at $314,075,000. Ranger Investment Management L.P. bought a new position in shares of LeMaitre Vascular during the 2nd quarter worth about $21,045,000. Rice Hall James & Associates LLC bought a new position in shares of LeMaitre Vascular during the 2nd quarter worth about $18,223,000. Bank of New York Mellon Corp acquired a new position in shares of LeMaitre Vascular during the second quarter valued at about $16,549,000. Finally, Grandeur Peak Global Advisors LLC acquired a new position in shares of LeMaitre Vascular during the second quarter valued at about $15,451,000. Institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock opened at $87.92 on Thursday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.96 and a current ratio of 16.31. The firm's 50-day simple moving average is $81.38 and its 200-day simple moving average is $94.16. LeMaitre Vascular, Inc. has a twelve month low of $78.22 and a twelve month high of $118.01. The firm has a market cap of $2.01 billion, a P/E ratio of 30.85, a price-to-earnings-growth ratio of 2.32 and a beta of 0.51.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.65 EPS for the quarter, missing analysts' consensus estimates of $0.69 by ($0.04). LeMaitre Vascular had a return on equity of 15.63% and a net margin of 25.02%. The business had revenue of $67.97 million for the quarter, compared to the consensus estimate of $67.39 million. During the same quarter in the prior year, the business earned $0.75 EPS. The firm's revenue for the quarter was up 11.3% on a year-over-year basis. As a group, research analysts expect that LeMaitre Vascular, Inc. will post 2.89 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Thursday, November 19th will be paid a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 1.1%. The ex-dividend date is Thursday, November 19th. LeMaitre Vascular's dividend payout ratio is currently 35.09%.

Analyst Upgrades and Downgrades

LMAT has been the subject of several research reports. Barrington Research cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Wednesday, August 5th. Wall Street Zen lowered LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Weiss Ratings cut LeMaitre Vascular from a "buy (b-)" rating to a "hold (c+)" rating in a report on Friday, October 23rd. Citigroup reaffirmed a "market outperform" rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Finally, Wells Fargo & Company reduced their price objective on LeMaitre Vascular from $104.00 to $94.00 and set an "equal weight" rating for the company in a research report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $110.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a medical device company focused on the treatment of peripheral vascular disease. The company develops, manufactures and markets products used primarily by vascular surgeons and other specialists in open vascular surgery procedures.

Its product portfolio includes biological and synthetic vascular grafts, carotid shunts, embolectomy and thrombectomy catheters, valvulotomes, vessel closure devices, vascular patches and surgical instruments. These products are designed to support procedures involving the arteries and veins, including the repair, reconstruction and treatment of diseased or obstructed blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular sells its products through a combination of direct sales personnel and distributors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.